Yahoo Web Search

Sign In

Search results

  1. pharmaphorum.com › views-and-analysis › eisai_current_focusEisai: current focus and pipelines – interview with Gary Hendler

    2 days ago · pharmaphorum interviews Gary Hendler of Eisai to hear of Eisai’s current pipeline and what disease areas it will be focussing on.

  2. www.euractiv.com › section › health-consumersAlzheimer’s drug lecanemab, EMA re-examining marketing...

    2 days ago · Eisai is committed to working with the CHMP and other relevant authorities with the aim of making the treatment available in the EU,” Eisai EMEA Regional Chairman and CEO Gary Hendler told...

  3. www.euractiv.fr › section › innovation-en-santeAlzheimer : l’Agence européenne des médicaments réexamine le cas...

    1 day ago · Eisai s’engage à travailler avec le CHMP et les autres autorités compétentes dans le but de rendre le traitement disponible dans l’UE », explique Gary Hendler, président-directeur général régional d’Eisai EMEA, à Euractiv.

  4. pharmaphorum.com › news › eisai-disappointed-nice-rejectsEisai disappointed after NICE rejects earlier use for breast...

    Sep 18, 2024 · But Gary Hendler, Chief Commercial Officer Eisai Oncology Business Group, and chairman and CEO Eisai EMEA said he was “disappointed” after another knock-back from NICE.

  5. pharmaphorum.com › news › eisai_to_enter_russian_pharma_marketEisai to enter Russian pharma market | pharmaphorum

    Sep 16, 2024 · Gary Hendler, Eisai President &amp, CEO, Russia and EMEA. The Russian healthcare market is one of the fastest growing markets in the world. The pharmaceutical industry has seen...

  6. www.reuters.com › markets › companies4523.T - | Stock Price & Latest News | Reuters

    4 days ago · Gary Hendler Managing Executive Officer, President of EMEA Region, Chairman & Chief Executive Officer of Subsidiary

  7. en.euractiv.eu › section › health-consumersAlzheimer’s drug lecanemab, EMA re-examining marketing...

    2 days ago · The European Medicines Agency’s human medicines committee is re-examining the marketing authorisation application for the Alzheimer’s disease (AD) drug lecanemab, a treatment that has been shown to slow cognitive decline.